Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

Shigeo Yamazaki, Ikuo Sekine, Yoshihiro Matsuno, Hidefumi Takei, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Tetsuro Kodama, Hisao Asamura, Ryosuke Tsuchiya, Nagahiro Saijo

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalLung Cancer
Volume49
Issue number2
DOIs
Publication statusPublished - 2005 Aug
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Cisplatin
Drug Therapy
Lung
Vindesine
Mitomycin
Etoposide
Lung Neoplasms

Keywords

  • Chemotherapy
  • Cisplatin
  • Lung cancer
  • Neuroendocrine carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Yamazaki, S., Sekine, I., Matsuno, Y., Takei, H., Yamamoto, N., Kunitoh, H., ... Saijo, N. (2005). Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer, 49(2), 217-223. https://doi.org/10.1016/j.lungcan.2005.01.008

Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. / Yamazaki, Shigeo; Sekine, Ikuo; Matsuno, Yoshihiro; Takei, Hidefumi; Yamamoto, Noboru; Kunitoh, Hideo; Ohe, Yuichiro; Tamura, Tomohide; Kodama, Tetsuro; Asamura, Hisao; Tsuchiya, Ryosuke; Saijo, Nagahiro.

In: Lung Cancer, Vol. 49, No. 2, 08.2005, p. 217-223.

Research output: Contribution to journalArticle

Yamazaki, S, Sekine, I, Matsuno, Y, Takei, H, Yamamoto, N, Kunitoh, H, Ohe, Y, Tamura, T, Kodama, T, Asamura, H, Tsuchiya, R & Saijo, N 2005, 'Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy', Lung Cancer, vol. 49, no. 2, pp. 217-223. https://doi.org/10.1016/j.lungcan.2005.01.008
Yamazaki, Shigeo ; Sekine, Ikuo ; Matsuno, Yoshihiro ; Takei, Hidefumi ; Yamamoto, Noboru ; Kunitoh, Hideo ; Ohe, Yuichiro ; Tamura, Tomohide ; Kodama, Tetsuro ; Asamura, Hisao ; Tsuchiya, Ryosuke ; Saijo, Nagahiro. / Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. In: Lung Cancer. 2005 ; Vol. 49, No. 2. pp. 217-223.
@article{3ca0f4af501a4b2aad281e88205d53f6,
title = "Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy",
abstract = "Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50{\%}. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64{\%}) was significantly different from that in previously treated patients (17{\%}). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.",
keywords = "Chemotherapy, Cisplatin, Lung cancer, Neuroendocrine carcinoma",
author = "Shigeo Yamazaki and Ikuo Sekine and Yoshihiro Matsuno and Hidefumi Takei and Noboru Yamamoto and Hideo Kunitoh and Yuichiro Ohe and Tomohide Tamura and Tetsuro Kodama and Hisao Asamura and Ryosuke Tsuchiya and Nagahiro Saijo",
year = "2005",
month = "8",
doi = "10.1016/j.lungcan.2005.01.008",
language = "English",
volume = "49",
pages = "217--223",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

AU - Yamazaki, Shigeo

AU - Sekine, Ikuo

AU - Matsuno, Yoshihiro

AU - Takei, Hidefumi

AU - Yamamoto, Noboru

AU - Kunitoh, Hideo

AU - Ohe, Yuichiro

AU - Tamura, Tomohide

AU - Kodama, Tetsuro

AU - Asamura, Hisao

AU - Tsuchiya, Ryosuke

AU - Saijo, Nagahiro

PY - 2005/8

Y1 - 2005/8

N2 - Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.

AB - Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. Methods: Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed. Results: Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%). Conclusions: Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.

KW - Chemotherapy

KW - Cisplatin

KW - Lung cancer

KW - Neuroendocrine carcinoma

UR - http://www.scopus.com/inward/record.url?scp=22044450203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044450203&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.01.008

DO - 10.1016/j.lungcan.2005.01.008

M3 - Article

C2 - 16022916

AN - SCOPUS:22044450203

VL - 49

SP - 217

EP - 223

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -